These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38540686)

  • 21. Clinical significance and functional role of transmembrane protein 47 (TMEM47) in chemoresistance of hepatocellular carcinoma.
    Ng KT; Yeung OW; Liu J; Li CX; Liu H; Liu XB; Qi X; Ma YY; Lam YF; Lau MY; Qiu WQ; Shiu HC; Lai MK; Lo CM; Man K
    Int J Oncol; 2020 Oct; 57(4):956-966. PubMed ID: 32945373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker.
    Marshall A; Lukk M; Kutter C; Davies S; Alexander G; Odom DT
    PLoS One; 2013; 8(3):e59459. PubMed ID: 23527199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
    Feng F; Jiang Q; Cao S; Cao Y; Li R; Shen L; Zhu H; Wang T; Sun L; Liang E; Sun H; Chai Y; Li X; Liu G; Yang R; Yang Z; Yang Y; Xin S; Li BA
    Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
    Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
    Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
    Lai YL; Wang KH; Hsieh HP; Yen WC
    J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
    Qin J; Luo M; Qian H; Chen W
    Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.
    Lu JC; Zhang PF; Huang XY; Guo XJ; Gao C; Zeng HY; Zheng YM; Wang SW; Cai JB; Sun QM; Shi YH; Zhou J; Ke AW; Shi GM; Fan J
    J Hematol Oncol; 2021 Nov; 14(1):200. PubMed ID: 34838121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3.
    Shu G; Su H; Wang Z; Lai S; Wang Y; Liu X; Dai L; Bi Y; Chen W; Huang W; Zhou Z; He S; Dai H; Tang B
    J Exp Clin Cancer Res; 2021 Jan; 40(1):45. PubMed ID: 33499874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
    Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma.
    Liu J; Nie C
    Anticancer Drugs; 2022 Oct; 33(9):840-849. PubMed ID: 35946516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
    Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
    Chen YT; Xiang D; Zhao XY; Chu XY
    Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma.
    Mok EHK; Leung CON; Zhou L; Lei MML; Leung HW; Tong M; Wong TL; Lau EYT; Ng IOL; Ding J; Yun JP; Yu J; Zhu HL; Lin CH; Lindholm D; Leung KS; Cybulski JD; Baker DM; Ma S; Lee TKW
    Cancer Res; 2022 Sep; 82(17):3102-3115. PubMed ID: 35767704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dimeric oxyberberine CT4-1 targets LINC02331 to induce cytotoxicity and inhibit chemoresistance via suppressing Wnt/β-catenin signaling in hepatocellular carcinoma.
    Lin X; Chen J; Li X; Chen D; Luo K; Deng Y; Yang D; Huang Z; Tao C
    Arch Toxicol; 2023 Jun; 97(6):1627-1647. PubMed ID: 37120773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells.
    Yin X; Zheng SS; Zhang L; Xie XY; Wang Y; Zhang BH; Wu W; Qiu S; Ren ZG
    Gene; 2017 Jan; 596():53-88. PubMed ID: 27729273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
    Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
    Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional Roles of SPINK1 in Cancers.
    Lin TC
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma.
    Lauschke VM; Nordling Å; Zhou Y; Fontalva S; Barragan I; Ingelman-Sundberg M
    Pharmacogenomics; 2019 Oct; 20(15):1085-1092. PubMed ID: 31588878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.